Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...

NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are ...

Viking Therapeutics (NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of today ...

Viking Therapeutics shares rose Monday morning before reversing course and declining after reporting the latest results from ...

Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...

Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...

The stock VKTX, which enjoys the unusual position of having all buy ratings from the 13 analysts offering coverage on FactSet ...

Viking Therapeutics (VKTX) surges on promising obesity drug results. Explore key price levels and analyst insights in this detailed analysis.

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

Investing.com - Viking Therapeutics Inc (NASDAQ: VKTX) reported fourth quarter EPS of $-0.260, $0.03 worse than the analyst estimate of $-0.230. Revenue for the quarter came in at ...